Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9401639 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL10353052 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL8138421 | 0.91 | MAPT (0.50) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL26080815 | 0.86 | MAPT (0.47) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6508831 | 0.86 | ALDH1A1 (0.72) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL6508829 | 0.86 | ALDH1A1 (0.72) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL10350417 | 0.85 | ALDH1A1 (0.69) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL10353050 | 0.84 | MAPT (0.57) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL8036277 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1TDP1GLAPOLB | |
| SCHEMBL9401431 | 0.84 | CA1 (0.54) | KDM4EALDH1A1TDP1GLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814490-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| EP-2814490-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8629276-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629276-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8609653-B2 | Azaindole compounds and methods for treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2013123148-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210857-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210857-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-5286869-A | Vasodilators and anticoagulants | FUJIREBIO KABUSHIKI KAISHA (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0380589-B1 | PROCESSES FOR PREPARING ALKYLENE AND DIALKYL KETALS AND ALKYL ALPHA-ENOL ETHERS OF ALPHA-ACETYL CINNAMIC ACIDS OR ESTERS THEREOF | EASTMAN KODAK CO (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0403957-A2 | Optical active 1,4-dihydropyridine derivates | FUJIREBIO INC. (JP) | 1990-12-27 | — | — | EP | disclosed |
| EP-0380585-A1 | PROCESS FOR PREPARING 2-NAPHTHANOIC ACIDS AND ESTERS THEREOF | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-08-08 | — | — | EP | disclosed |
| WO-1989003377-A1 | PROCESS FOR PREPARING 2-NAPHTHANOIC ACIDS AND ESTERS THEREOF | EASTMAN KODAK COMPANY (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4786748-A | Processes for preparing aklylene and dialkyl ketals and alkyl alpha-enol ethers of alpha-acetyl cinnamic acids or esters thereof | EASTMAN KODAK COMPANY (US) | 1988-11-22 | — | — | US | disclosed |
| US-4761497-A | Process for preparing 2-naphthanoic acids and esters thereof | EASTMAN KODAK COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | KDM4E 199/4885ALDH1A1 1779/4885TDP1 1103/4885 |
| US-20130210857-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | KDM4E 2143/4885ALDH1A1 3327/4885TDP1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.